— Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older
July 27, 2026
• 2 min read
The FDA approved oral centanafadine (Simtriyo), a first-in-class triple reuptake inhibitor for attention deficit-hyperactivity disorder (ADHD), Otsuka announced late last week.
The once-daily extended-release capsule -- a norepinephrine, dopamine, and serotonin reuptake inhibitor that functions as a central nervous system stimulant -- is indicated for patients ages 6 years and older who weigh at least 20 kg (44 lb).
